52 results
Page 2 of 3
8-K
EX-1.1
vkx9a8u13a0igqnq
10 Jan 22
Entry into a Material Definitive Agreement
8:05am
424B5
fch erec5kk
10 Jan 22
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
31z6 jdntwuyvdq
2 Nov 21
Agile Therapeutics Reports Third Quarter 2021 Financial Results
4:11pm
424B5
jp0y4066 2r2yv
8 Oct 21
Prospectus supplement for primary offering
5:21pm
424B5
1ej ij771ujmbb1aj
7 Oct 21
Prospectus supplement for primary offering
5:24pm
8-K
EX-1.1
gz4m v6uqcw1c
18 Mar 21
Entry into a Material Definitive Agreement
5:13pm
424B5
1un0q379t wkik8yiqg
18 Mar 21
Prospectus supplement for primary offering
5:01pm
8-K
EX-99.1
k18490imzru mpvsq
1 Mar 21
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.1
4zbjcx8fr9hlh
14 Jan 21
Results of Operations and Financial Condition
8:30am
8-K
EX-1.1
n6tspu4f39m
21 Feb 20
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
4:46pm
8-K
EX-10.1
92y0yxm6d93h2 h8n00y
12 Feb 20
Entry into a Material Definitive Agreement
8:00am